Comments	Responses
1.The guideline did not discuss the emerging data on the role or HER2 Receptor status/treatment in DCIS	This study did not meet the prespecified criteria of this systematic review.
2.Suggest adding “evidence does not strong favor” to the beginning of Recommendation 1 and 6.	The Working Group has decided to leave the recommendations as is.
3.Suggest mentioning RT option after BCS for context in Recommendation 1 as an enabler to patients making the decision about BCS vs. mastectomy (and state “see Recommendation 5 below”)	We have added a phrase in a qualifying statement to indicate that RT options after BCS are covered in Recommendation 5 below.
4.Since there is a lack of conclusive evidence for Recommendation 4 consider adding “Molecular profile testing should be confined to ongoing research”	The Working Group has added this phrase to recommendation 4.
5.Would consider adding most recent trial on low dose tamoxifen (TAM-01)	This study did not meet the prespecified criteria of this systematic review as the number of DCIS patients comprised less than 80% of the patient population and did not provide a separate analysis. More information can be found on page 51.
6.Recommendation 5.1 should be reworded to give an age component with lower Grade DCIS as there is much discussion globally to de-escalate therapy for elderly women	The Working Group has decided to leave the recommendation as it. The potential risks and benefits of adjuvant irradiation should be discussed between individual patient and clinicians.